Published on 01 October 2024 As of 23 September 2024, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of Reteplase (10 units lyophilized powder for IV injection) for ST-Elevation Myocardial Infarction (STEMI) Patients for possible inclusion in the Philippine National Formulary (PNF). As such, the HTA Council hereby makes continue reading : [FOR PUBLIC CONSULTATION] HTA Council Preliminary Recommendation on Reteplase (10 units lyophilized powder for IV injection) for ST-Elevation Myocardial Infarction (STEMI) Patients
[FOR PUBLIC CONSULTATION] HTA Council Preliminary Recommendation on Citicoline For Ischemic Stroke
Published 25 September 2024 As of 20 September 2024, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of Citicoline for Ischemic Stroke Patients for possible inclusion in the Philippine National Formulary (PNF). As such, the HTA Council hereby makes public its preliminary recommendation on the non-inclusion in the PNF continue reading : [FOR PUBLIC CONSULTATION] HTA Council Preliminary Recommendation on Citicoline For Ischemic Stroke
[FOR PUBLIC CONSULTATION] HTA Council Preliminary Recommendation on Pneumococcal Conjugate Vaccines (PCV) for infants less than 1 year old and children aged 13 to 23 months for catch-up immunization
Published 25 September 2024 As of 20 September 2024, the Health Technology Assessment Council (HTA Council) has completed the evidence appraisal on the assessment of Pneumococcal Conjugate Vaccines (PCV) for Infants less than 1 year old and children aged 13 to 23 months for catch-up immunization. The HTA Council assessed the following PCV products for continue reading : [FOR PUBLIC CONSULTATION] HTA Council Preliminary Recommendation on Pneumococcal Conjugate Vaccines (PCV) for infants less than 1 year old and children aged 13 to 23 months for catch-up immunization
HTA Council Recommendation on Calcium Hydroxide 80% + Clinoptilolite 20% (Kiti-kitiX) Larvicide
As per the Department of Health (DOH) Department Circular 2024 -0308 published 31 July 2024, the Secretary of Health (SOH) fully concurs with the HTA Council recommendation on the non-financing and non-inclusion of Calcium Hydroxide 80% + Clinoptilolite 20% (Kiti-kitiX) Larvicide in the list of larvicides to be used by the Aedes Borne Viral Diseases continue reading : HTA Council Recommendation on Calcium Hydroxide 80% + Clinoptilolite 20% (Kiti-kitiX) Larvicide
Zoledronic acid for prevention of skeletal-related events in cancer patients
Status: Ongoing assessment